October 10, 2023
Ohio Open Public Draft/Revised LCD Discussion Meeting: November 8, 2023
CGS will host a Ohio Open Meeting both onsite and via Microsoft Teams for comments from providers and the general public related to the development and or revision of Local Coverage Determinations (LCDs) for Medicare Jurisdiction 15.
Date: |
November 8th, 2023 |
Time: |
4:00-5:00 p.m. ET (3:00-5:00 CT) |
Place: |
Onsite: For those unable to attend in person, the meeting will also be available via Microsoft Teams. To attend virtually you must register via the following link. |
Please note that this is the Open Public meeting to discuss Draft LCDs or Revisions to current LCDs and not the Contractor Advisory Committee Meetings (CAC).
The following draft LCD(s) will be discussed:
- DL38582/DA58061 MolDX: Molecular Testing for Solid Organ Allograft Rejection
- DL38662/DA58127 Implantable Continuous Glucose Monitors (I-CGM)
- DL39648/DA59472 MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers
- DL39650/DA59474 MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules
- DL39656/DA59480 Trigger Point Injections (TPI)
- DL39658/DA59482 MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy
NOTE: DL38582/DA58061, DL38662/DA58127, DL39648/DA59472, and DL39650/ DA59474 will not post to the CMS Medicare Coverage Database until 10/12/23.
Link to the Draft LCDs: Ohio Proposed/Draft LCDs Not Released to Final
Interested parties who wish to make presentations related to the draft LCD must submit a written request, no later than 10/24/2023 to CMD.Inquiry@cgsadmin.com and include the following information:
- Name, address, telephone number and e-mail address of presenter
- Name, address, telephone number and e-mail address of organization
- Name of draft LCD
- Copy of the presentation(s)
- Completed Conflict of Interest (COI) Form for each topic you wish to present.
- DL38582/ DA58061 MolDX: Molecular Testing for Solid Organ Allograft Rejection
- DL38662/DA58127 Implantable Continuous Glucose Monitors (I-CGM)
- DL39648/DA59472 MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers
- DL39650/ DA59474 MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules )
- DL39656/ DA59480 Trigger Point Injections (TPI)
- DL39658/ DA59482 MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy
The presentation and COI form must be attached to your request(s). Each presenter will have equal time based on the number of presentations requested. Once all requests are received, we will notify each presenter of the time allocation via email approximately one week prior to the meeting.
Future Meetings
Onsite meetings are tentative and could be changed to joint teleconference/webinar.
- TBA